Aggressive Macroprolactinoma Refractory to Multiple Lines of Localized and Systemic Therapy
Open Access
- 3 December 2025
- journal article
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (1)
Abstract
Aggressive prolactinomas are rare and pose considerable therapeutic challenges, especially in cases refractory to conventional treatments, including dopamine agonists, surgery, and radiotherapy. We present a case of a 77-year-old man with refractory, treatment-resistant macroprolactinoma and describe the sequential use of capecitabine temozolomide, olaparib bevacizumab, pembrolizumab, and pazopanib. Despite disease progression on multiple lines of therapy, pazopanib achieved disease stability, after which the tumor demonstrated slow progression. This case highlights the urgent need for novel therapeutic approaches and predictive biomarkers in managing refractory aggressive prolactinomas.Keywords
This publication has 9 references indexed in Scilit:
- Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to TreatmentThe Journal of Clinical Endocrinology & Metabolism, 2023
- Aggressive prolactinoma (Review)Experimental and Therapeutic Medicine, 2021
- The Epidemiology of Pituitary AdenomasEndocrinology and Metabolism Clinics of North America, 2020
- Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-AnalysisFrontiers in Oncology, 2020
- Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016European Journal of Endocrinology, 2018
- European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomasEuropean Journal of Endocrinology, 2018
- PARP inhibitors: Synthetic lethality in the clinicScience, 2017
- Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With TemozolomideThe Journal of Clinical Endocrinology & Metabolism, 2015
- Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activityMolecular Cancer Therapeutics, 2007